Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company
Co-founder Cathal Friel has indicated that a series of spinouts could unlock £750 million for shareholders in the Dublin-based pharma company. Open Orphan, the Dublin-listed pharmaceutical services company run by
Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets. The company said the potential demerger is at an advanced
Dublin-listed pharmaceutical services company Open Orphan said it is planning for a possible spin-out of some of its non-core development intellectual property assets. The company said it believed the assets in question
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that it is
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary
The UK’s COVID-19 human challenge study has reached its first milestone after administering virus to three volunteers in a controlled clinical setting The first participants recruited to the landmark trial have now completed
Speculation is mounting that Open Orphan, a clinical trial company headed by Irish dealmaker Cathal Friel, will move to spin off its stake in vaccine developer Imutex via a Nasdaq
Dublin-listed pharmaceutical services company Open Orphan’s subsidiary Hvivo has won a contract worth €7.5 million to run a human viral challenge study. Open Orphan, a European-focused, rare and orphan drug consulting services
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
